◢ TECHNICA.BIOBIOTECH ECOSYSTEM INTELLIGENCE
technica.bio / State of Biotech 2026
Annual report · 2026

The State of Biotech — 2026

93 companies across longevity, ADCs and the Polish scene — charted by stage, capital, geography and the signals the market is actually pricing.

93
companies tracked
37
in clinical trials
11
technologies
13
approved ADCs
$8.0B
longevity capital (priv.)
13.3B PLN
polish listed mkt cap

1 · What the market is pricing

Prediction markets are the one place the crowd bets real money on biotech outcomes — a clean read on sentiment. The thesis: a metabolic supercycle, gated by the regulatory clock, not the science.

Implied probability — key live markets

FDA approves retatrutide in 2026 · Drug · GLP-127%
RFK Jr. out as HHS Secretary by Dec 31, 2026 · Policy27%
New pandemic declared in 2026 · Public health10%
Hantavirus vaccine approved in 2026 · Vaccine6%

Polymarket implied probabilities, snapshot mid-2026 — they move constantly. Sentiment, not fact. Oral GLP-1s (orforglipron, oral semaglutide) already cleared/at FDA in 2026.

Obesity is the consensus boom — the retatrutide doubt is the FDA clock (no NDA filed yet), not efficacy. Reimbursement is the real catalyst — Medicare's GLP-1 Bridge starts July 2026. The priced risk is Washington (RFK/FDA), not a pandemic (~10%).

Bottom lineRide the incretin/metabolic wave and the reimbursement unlock; treat regulatory-regime risk as the variable to hedge.

2 · Where the innovation is

Companies by landscape

Longevity Pipeline
19
ADC Landscape
24
Polish Biotech Scene
50

Companies by technology

Antibody–Drug Conjugates
24
AI-Driven Drug Discovery
14
Partial Epigenetic Reprogramming
7
Senolytics
5
AAV Gene Therapy
3
GLP-1 & the Incretin Boom
2
CAR-T Cell Therapy
2
Radioligand Therapy (RLT)
2
Targeted Protein Degradation
1
mRNA Therapeutics
1
Regulatory T-cell (Treg) Therapy
1

Mapped via mechanism / focus heuristics across all landscapes.

Pipeline maturity (all companies)

Discovery / preclinical
17
In the clinic (Ph 1–3)
37
Approved / on market
39

3 · ADC consolidation

The modality big pharma is buying. Precedent acquisitions and alliances:

ADC mega-deals

Pfizer → Seagen
$43.0B
Merck → Daiichi (alliance)
$22.0B
Gilead → Immunomedics
$21.0B
AbbVie → ImmunoGen
$10.1B
Genmab → ProfoundBio
$1.8B

Headline transaction / alliance value, USD.

ADC landscape — target × payload class

target ↓ / payload →Topo-I inhibitorAuristatinMaytansinoidDNA-damagingDNA-crosslinker (PBD)Tubulin inhibitor
HER221
TROP23
CD301
Nectin-42
Tissue Factor1
CD79b1
FRα112
BCMA1
CD331
CD191
B7-H31
HER31
Claudin 18.21
B7-H41
c-Met1
Napi2b1

4 · Longevity capital

Best-funded longevity programs

Altos Labs
3.0B
Calico
2.5B
Retro Biosciences
1.0B
Insilico Medicine
400M
Life Biosciences
240M
Juvenescence
220M
Cambrian BioPharma
160M
Loyal
150M
NewLimit
130M
Rejuvenate Bio
50M

Disclosed private capital, USD — public-co names excluded.

Longevity pipeline by stage

Discovery
1
Preclinical
6
IND-enabling
4
Phase 1
4
Phase 2
3
Phase 3
1

5 · Poland — the BioIndex

A market-cap-weighted snapshot of listed Polish biotech (25 names, 13.3B PLN aggregate).

Polish BioIndex — weight by market cap

Diagnostyka
43.8%
Synektik
17.5%
Celon Pharma
8.5%
Selvita
4.3%
Captor Therapeutics
3.7%
Bioceltix
3.7%
Bioton
2.8%
Scope Fluidics
2.7%
Ryvu Therapeutics
2.5%
Medicalgorithmics
2.0%
Biomed-Lublin
1.5%
Molecure
1.1%
Mabion
1.0%
NanoGroup
0.7%
PolTREG
0.7%
Genomtec
0.7%
Urteste
0.5%
Read-Gene
0.5%
Milton Essex
0.5%
Pharmena
0.3%
Nestmedic
0.3%
Genomed
0.3%
Pure Biologics
0.2%
genXone
0.1%
Braster
0.1%

Approx market caps, 2026-06 (GPW/NewConnect). Listed names only.

Polish scene by capital tier

GPW Main Market
18
VC-backed (private)
10
GPW NewConnect
9
Seed / early-stage
7
Private / established
6

Polish scene by city (HQ)

Warsaw
17
Wrocław
8
Kraków
6
Łódź
4
Gdańsk
2
Poznań
2
Warsaw / Łódź
1
Kazuń Nowy
1
Gdańsk / Warsaw
1
Konstantynów Łódzki
1
Toruń
1
Pieńków
1
◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

No spam · ~1–2 emails/month · unsubscribe anytime.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.